Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 2 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thyroid Neoplasms 2 Thyroid Cancer, Papillary 1 Sexual Dysfunction, Physiological 1 Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1 Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 38 Blood Specimen Collection 38 Bevacizumab 22 Surveys and Questionnaires 18 Standard of Care 18 Radiotherapy 17 Exercise 17 Carboplatin 17 Nivolumab 15 atezolizumab 14 Paclitaxel 14 Cisplatin 14 Drug Therapy 13 Fluorouracil 12 Cyclophosphamide 12 Cetuximab 11 Trastuzumab 10 Pemetrexed 10 Leucovorin 10 Docetaxel 10 Dexamethasone 10 Oxaliplatin 9 Biopsy 9 pertuzumab 8 olaparib 8 Temozolomide 8 Panitumumab 8 Observation 8 Irinotecan 8 abemaciclib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasms × selpercatinib × Clear all

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡